Pulse Biosciences, Inc. PLSE
Pulse Biosciences, Inc. (Nasdaq: PLSE) is a cardio-renal-metabolic medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| nPulse Cardiac Catheter System | paroxysmal atrial fibrillation (US pivotal IDE study enrolling; PMA expected) | — | NA_NON_THERAPEUTIC |
| nPulse Cardiac Surgical Clamp | surgical treatment of atrial fibrillation (US pivotal IDE study enrolling; PMA planned) | — | NA_NON_THERAPEUTIC |
| nPulse Vybrance Percutaneous Electrode System | soft tissue / benign thyroid nodule ablation (510(k) cleared Mar 2024; limited market release) | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- MiniMed Group, Inc. MMED
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- AtriCure, Inc. ATRC
- LeMaitre Vascular, Inc. LMAT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.